Characteristics of the patients according to treatment arm
| . | QT + V, n = 129 . | TD, n = 127 . | VTD, n = 130 . |
|---|---|---|---|
| Median age, y | 57 | 56 | 56 |
| Sex, male/female, % | 52/48 | 54/46 | 55/45 |
| M-protein type, % | |||
| IgG | 61 | 55 | 65 |
| IgA | 21 | 25 | 19 |
| Light chain | 15 | 17 | 12 |
| IgD | 2 | 3 | 3 |
| IgM | 1 | 0 | 1 |
| Hb < 10 g/dL, % | 37 | 32 | 27 |
| EMP, % | 13 | 18 | 20 |
| Poor cytogenetics: t(4;14), t(14;16), del(17p), % | 18 | 17 | 18 |
| . | QT + V, n = 129 . | TD, n = 127 . | VTD, n = 130 . |
|---|---|---|---|
| Median age, y | 57 | 56 | 56 |
| Sex, male/female, % | 52/48 | 54/46 | 55/45 |
| M-protein type, % | |||
| IgG | 61 | 55 | 65 |
| IgA | 21 | 25 | 19 |
| Light chain | 15 | 17 | 12 |
| IgD | 2 | 3 | 3 |
| IgM | 1 | 0 | 1 |
| Hb < 10 g/dL, % | 37 | 32 | 27 |
| EMP, % | 13 | 18 | 20 |
| Poor cytogenetics: t(4;14), t(14;16), del(17p), % | 18 | 17 | 18 |
QT + V indicates chemotherapy + bortezomib; TD, thalidomide/dexamethasone; VTD, bortezomib/thalidomide/dexamethasone; Hb, hemoglobin; and EMP: extramedullary plasmacytomas